Boston Scientific launches the Precision NOVI™ Spinal Cord Stimulator System in Europe
June 04, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering
Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available. The enhanced shape of the Precision Novi implant is designed to provide a new level of comfort to patients with pain treated using primary cell therapy. Precision Novi is powered by Illumina 3D™ Software that enables physicians to target pain precisely with point-and-click simplicity.
Chronic pain can have a devastating impact on quality of life for many patients. Spinal cord stimulators alleviate pain by stimulating the nerve fibers in the spinal cord to reduce pain signals. While primary cell (also referred to as non-rechargeable) devices are typically larger due to limitations in technology and battery size, the Precision Novi System represents a significant technology advance, with the smallest high-capacity battery on the market, allowing effective pain relief to be delivered from a much smaller device. The Precision Novi System is also the only primary cell device that couples with a wireless remote , empowering patients with flexibility and control over their pain management.
“The small size and novel shape of the Precision Novi implant improves patient comfort and enables a very discreet subcutaneous placement,” said Dr. Simon Thomson, a consultant in Pain Management and Neuromodulation at Basildon and Thurrock University Hospitals, UK. “The simplicity of the programming software saves valuable time in the operating theatre, efficiently allowing me to achieve and maintain comfortable therapy for my patients.”
Unlike any other primary cell system, the Precision Novi intuitive Illumina 3D™ neural targeting software incorporates three-dimensional lead location, as well as the conductivity of the spinal cord and surrounding tissue. This point-and-click technology automatically calculates the optimal programming configuration to target the selected pain area. Further, unique for primary cell devices, Precision Novi is a MultiWave Platform capable of delivering a variety of field shapes and waveforms with or without paresthesia, including burst and higher rate frequencies.
“We are excited to expand upon our range of therapeutic solutions for patients suffering from chronic pain,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. “The Precision Novi System brings the power of our Illumina 3D Algorithm to the more than sixty percent of SCS patients in Europe who are treated with primary cell therapy.”
The Precision Novi SCS System is not available in the United States. Comparative statements true as of June 4, 2015.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.eu and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding product launches, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.